Press Releases

Press Releases

DateTitle 
Jan 10, 2019
Company on track to submit Investigational New Drug application for CPI-818 in early 2019 BURLINGAME, Calif. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely
Jan 08, 2019
Both CPI-006 monotherapy and CPI-006 in combination with CPI-444 trial arms  now enrolling patients at U.S. sites CPI-006 in combination with CPI-444 targets multiple points in the adenosine pathway BURLINGAME, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.